{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:20:36Z","timestamp":1787718036669,"version":"build-2784847793"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ero.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:50:31Z","timestamp":1770025831000},"page":"199-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6451-3058","authenticated-orcid":false,"given":"Pauline M","family":"Bovens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike HM","family":"Wientjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatke","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons A","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ero.2026.01.004_bib0001","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ero.2026.01.004_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.ero.2026.01.004_bib0003","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/iid3.780","article-title":"Risk of hepatitis B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: a meta-analysis","volume":"11","author":"Hong","year":"2023","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"10.1016\/j.ero.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ero.2026.01.004_bib0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-017-9817-y","article-title":"Risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis","volume":"11","author":"Tang","year":"2017","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.ero.2026.01.004_bib0007","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3899\/jrheum.151105","article-title":"Low risk of hepatitis B virus reactivation in HBsAg-negative\/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study","volume":"43","author":"Varisco","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2026.01.004_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.11.024","article-title":"Patients treated with rituximab are poorly screened for hepatitis B infection: data from a low-incidence country","volume":"108","author":"Brakenhoff","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.ero.2026.01.004_bib0009","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/imj.13740","article-title":"Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence","volume":"48","author":"Hall","year":"2018","journal-title":"Intern Med J"},{"issue":"12","key":"10.1016\/j.ero.2026.01.004_bib0010","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s10067-018-4096-0","article-title":"Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis","volume":"37","author":"Su","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.01.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120749","article-title":"Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening","volume":"10","author":"Visram","year":"2015","journal-title":"PLoS One"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:51:24Z","timestamp":1787716284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050708126000042"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.01.004","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}